These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 20097953)

  • 21. Paraoxonases: structure, gene polymorphism & role in coronary artery disease.
    Gupta N; Gill K; Singh S
    Indian J Med Res; 2009 Oct; 130(4):361-8. PubMed ID: 19942738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Paraoxonase 1 and atherosclerosis-related diseases.
    Kotur-Stevuljević J; Vekić J; Stefanović A; Zeljković A; Ninić A; Ivanišević J; Miljković M; Sopić M; Munjas J; Mihajlović M; Spasić S; Jelić-Ivanović Z; Spasojević-Kalimanovska V
    Biofactors; 2020 Mar; 46(2):193-205. PubMed ID: 31400246
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Paraoxonase: its multiple functions and pharmacological regulation].
    Fridman O; Fuchs AG; Porcile R; Morales AV; Gariglio LO
    Arch Cardiol Mex; 2011; 81(3):251-60. PubMed ID: 21975240
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacological Interactions of Paraoxonase 1 (PON1): A HDL-Bound Antiatherogenic Enzyme.
    Mahrooz A
    Curr Clin Pharmacol; 2016; 11(4):259-264. PubMed ID: 27633038
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paraoxonase 1 activities, regulation, and interactions with atherosclerotic lesion.
    Aviram M; Vaya J
    Curr Opin Lipidol; 2013 Aug; 24(4):339-44. PubMed ID: 23508039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention.
    Mackness MI; Durrington PN; Mackness B
    Am J Cardiovasc Drugs; 2004; 4(4):211-7. PubMed ID: 15285696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Paraoxonase 1 (PON1) is a more potent antioxidant and stimulant of macrophage cholesterol efflux, when present in HDL than in lipoprotein-deficient serum: relevance to diabetes.
    Rosenblat M; Karry R; Aviram M
    Atherosclerosis; 2006 Jul; 187(1):74-81. PubMed ID: 16229851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Paraoxonase and coronary heart disease.
    Mackness MI; Mackness B; Durrington PN; Fogelman AM; Berliner J; Lusis AJ; Navab M; Shih D; Fonarow GC
    Curr Opin Lipidol; 1998 Aug; 9(4):319-24. PubMed ID: 9739487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Variation in paraoxonase-1 activity and atherosclerosis.
    Soran H; Younis NN; Charlton-Menys V; Durrington P
    Curr Opin Lipidol; 2009 Aug; 20(4):265-74. PubMed ID: 19550323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Age-related decrease in high-density lipoproteins antioxidant activity is due to an alteration in the PON1's free sulfhydryl groups.
    Jaouad L; de Guise C; Berrougui H; Cloutier M; Isabelle M; Fulop T; Payette H; Khalil A
    Atherosclerosis; 2006 Mar; 185(1):191-200. PubMed ID: 16026789
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of paraoxonase 192/55 polymorphism in an Iranian population.
    Sepahvand F; Rahimi-Moghaddam P; Shafiei M; Ghaffari SM; Rostam-Shirazi M; Mahmoudian M
    J Toxicol Environ Health A; 2007 Jul; 70(13):1125-9. PubMed ID: 17558807
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of PON1 polymorphism on HDL antioxidant potential is blunted with aging.
    Cherki M; Berrougui H; Isabelle M; Cloutier M; Koumbadinga GA; Khalil A
    Exp Gerontol; 2007 Aug; 42(8):815-24. PubMed ID: 17532162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2.
    Ng CJ; Bourquard N; Grijalva V; Hama S; Shih DM; Navab M; Fogelman AM; Lusis AJ; Young S; Reddy ST
    J Biol Chem; 2006 Oct; 281(40):29491-500. PubMed ID: 16891303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important?
    Mackness M; Mackness B
    Free Radic Biol Med; 2004 Nov; 37(9):1317-23. PubMed ID: 15454272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Paraoxonase 1 and homocysteine metabolism.
    Perła-Kaján J; Jakubowski H
    Amino Acids; 2012 Oct; 43(4):1405-17. PubMed ID: 22643843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of paraoxonase 1 192 Q/R polymorphism on paraoxonase and acetylcholinesterase enzyme activities in a Turkish population exposed to organophosphate.
    Sunay SZ; Kayaaltı Z; Bayrak T; Söylemezoğlu T
    Toxicol Ind Health; 2015 Dec; 31(12):1061-8. PubMed ID: 23625910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of dietary lipids on paraoxonase-1 activity and gene expression.
    Ferretti G; Bacchetti T
    Nutr Metab Cardiovasc Dis; 2012 Feb; 22(2):88-94. PubMed ID: 22118836
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Paraoxonase 1 attenuates human plaque atherogenicity: relevance to the enzyme lactonase activity.
    Tavori H; Vaya J; Aviram M
    Adv Exp Med Biol; 2010; 660():99-111. PubMed ID: 20221874
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The development of human sera tests for HDL-bound serum PON1 and its lipolactonase activity.
    Gaidukov L; Tawfik DS
    J Lipid Res; 2007 Jul; 48(7):1637-46. PubMed ID: 17435182
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Determinants of homocysteine-thiolactonase activity of the paraoxonase-1 (PON1) protein in humans.
    Lacinski M; Skorupski W; Cieslinski A; Sokolowska J; Trzeciak WH; Jakubowski H
    Cell Mol Biol (Noisy-le-grand); 2004 Dec; 50(8):885-93. PubMed ID: 15704252
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.